Lactobacillus paracasei Lpc-37

Lactobacillus paracasei Lpc-37 is a probiotic strain that produces beneficial metabolites including short-chain fatty acids and bacteriocins. It supports digestive health by strengthening the intestinal barrier and modulating immune responses through interaction with Peyer's patches in the gut.

Origin & History

Lactobacillus paracasei Lpc-37 is a probiotic strain isolated from dairy products. It is recognized for its role in enhancing gut health and immunity.

Historical & Cultural Context

Fermented dairy products containing probiotics like Lactobacillus paracasei have been consumed for centuries for their health benefits.

Health Benefits

- Supports digestive health and regularity by promoting a balanced gut microbiome, which enhances nutrient absorption. - Enhances immune response by stimulating the production of antibodies and reducing inflammation. - May reduce symptoms of allergies by modulating immune system responses and reducing histamine levels. - Supports skin health by reducing inflammation and promoting a balanced microbiome. - Aids in weight management by improving metabolic rate and reducing fat storage. - Supports mental health by producing neurotransmitters that enhance mood and reduce anxiety. - Improves lactose digestion, making dairy products more tolerable for those with lactose intolerance.

How It Works

Lactobacillus paracasei Lpc-37 adheres to intestinal epithelial cells via surface proteins and produces short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. These metabolites strengthen tight junction proteins like claudin-1 and occludin, enhancing intestinal barrier function. The strain also stimulates dendritic cells in Peyer's patches, promoting regulatory T-cell differentiation and balanced Th1/Th2 immune responses.

Scientific Research

Lactobacillus paracasei Lpc-37 has been studied for its potential to improve gut health and enhance immune function, though more research is needed.

Clinical Summary

Clinical studies on Lactobacillus paracasei Lpc-37 include randomized controlled trials with 50-200 participants examining digestive and immune outcomes. Research shows improvements in stool consistency scores and reduction in gastrointestinal discomfort within 2-4 weeks of supplementation. Some studies report decreased inflammatory markers like TNF-α and IL-6, though sample sizes remain relatively small. Evidence quality is moderate, with most studies lasting 4-12 weeks.

Nutritional Profile

- Contains live probiotic cultures. - Supports gut flora balance. - Provides beneficial bacteria for digestive health.

Preparation & Dosage

Typical dosage ranges from 1 to 10 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus rhamnosus, Bifidobacterium breve, Galactooligosaccharides

Safety & Interactions

Lactobacillus paracasei Lpc-37 is generally well-tolerated with minimal side effects, occasionally causing mild bloating or gas during initial use. No significant drug interactions have been reported, though individuals on immunosuppressive medications should consult healthcare providers before use. The strain is contraindicated in severely immunocompromised patients or those with central venous catheters due to rare bacteremia risk. Safety during pregnancy and lactation has not been extensively studied.